Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed. The mechanisms underlying these BP reductions are incompletely...

Full description

Bibliographic Details
Main Authors: Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp, Richard G. IJzerman
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitor
Dapagliflozin
GLP-1 receptor agonist
Exenatide
Type 2 diabetes
Blood pressure
Online Access:https://doi.org/10.1186/s12933-022-01492-x

Internet

https://doi.org/10.1186/s12933-022-01492-x

Similar Items